A Short Time Assessment of Recombinant Human Granulocyte Colony-Stimulating Factor(rhg-Csf)in Treatment of Acute Cerebral Infarction

张俊,邓敏,张远锦,隋伟,王力平,孙阿萍,宋红松,鲁明,樊东升
DOI: https://doi.org/10.3969/j.issn.1003-2754.2006.02.002
2006-01-01
Abstract:Objective To assess the safety and efficacy of recombinant human granulocyte colony-stimulating factor(rhG-CSF)in the treatment of acute cerebral infarction by a randomized and placebo-controlled clinical trial. Method 50 cases with acute cerebral infarction were randomly allocated to receive treatment by either rhG-CSF or placebo within 1 week of stroke onset. The former included 25 cases were consecutively given rhG-CSF 2μg/kg for 5 days by subcutaneous injection. The other 25 cases were treated with placebo. The end points included NIH Stroke Scale and adverse reaction. Result In treatment group,there were statistically significant difference at NIH Stroke Scale on the 20th days of treatment (P=0. 004, P0. 01). There were also remarkable difference between two groups(P = 0. 007,P0. 01). Conclusions This study shows that rhG-CSF appears safe and effective for a-cute cerebral infarction during short time. It is necessary to have further study on the relations between its clinical efficacy and the dose,protocol of drugadministration and indication.
What problem does this paper attempt to address?